About Gemfrac
Indications for Gemfrac Use
Treatment of postmenopausal women with osteoporosis at high risk for fracture (a prior history of osteoporotic fracture, multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapies.
Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, or patients who have failed or are intolerant other available osteoporosis therapies.
Treatment on men and women with osteoporosis associated sustained systemic glucocorticoid therapy (daily dosage equivalent and women >5 mg of prednisone) at high risk for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies.
can help you to reduce the risk of another fracture.
How is Gemfrac supplied and what is its dose?
Gemfrac (teriparatide) is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge with Gemfrac delivery pen devise only for subcutaneous use only.
Each Gemfrac glass cartridge contains 750 ug of teriparatide in 3ml.
Each cartridge should be inserted into a delivery device to deliver 20 ug of teriparatide per dose each day for up to a 28 day period. The recommended dose for Gemfrac (teriparatide) is 20 µg subcutaneously once a day into the thigh or abdominal wall. Gemfrac (teriparatide) is administered via a multi-dose prefilled pen delivery device containing 28 daily doses of 20g. It should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur.
The delivery device should be stored under refrigeration at 2 to 8°C (36 to 46°F) at all times.
While the delivery device is in use, the time out of the refrigerator should be minimized, the dose may be delivered immediately following removal from the refrigerator
It is important to recap the delivery device when not in use to protect the cartridge from physical damage and light.